{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"10","value":"10.0"}]}],"title":"Everolimus"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"25","value":"25.0"}]}],"title":"Exemestane"}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"}],"units":"Participants"}],"description":"The dose intensity was calculated as the cumulative dose of everolimus or exemestane divided by the length of time on treatment during the first 56 days of treatment.","dispersionType":"Full Range","groups":[{"description":"Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or drink (NPO) for one hour after administration of the mouthwash. Also, participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations.","id":"OG000","title":"Dexamethasone Based Mouthwash"}],"paramType":"MEDIAN","populationDescription":"FAS: The FAS consisted of all participants who received at least one dose of study treatment (everolimus and/or exemestane) and at least one dose of investigational treatment (dexamethasone mouth wash).","reportingStatus":"POSTED","timeFrame":"56 days","title":"Dose Intensity of Everolimus and Exemestane","type":"SECONDARY","unitOfMeasure":"mg/day"}